Literature DB >> 8627748

Nuclear trafficking of influenza virus ribonuleoproteins in heterokaryons.

G Whittaker1, M Bui, A Helenius.   

Abstract

The influenza virus nucleoprotein (NP), matrix protein (M1), and ribonucleoproteins (vRNPs) undergo regulated nuclear import and export during infection. Their trafficking was analyzed by using interspecies heterokaryons containing nuclei from infected and uninfected cells. Under normal conditions, it was demonstrated that the vRNPs which were assembled in the nucleus and transported to the cytosol were prevented from reimport into the nucleus. To be import competent, they must first assemble into virions and enter by the endosomal entry pathway. In influenza virus mutant ts51, in which M1 is defective, direct reimport took place but was inhibited by heterologous expression of wild-type M1. These data confirm M1's role as the inhibitor of premature nuclear import and as the main regulator of nuclear transport of vRNPs. In addition to this vRNP shuttling, M1 also shuttled between the nucleus and the cytoplasm in ts51-infected cells. When NP was expressed in the absence of virus infection, it was also found to be a shuttling protein.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627748      PMCID: PMC190131     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export and inhibits import.

Authors:  K Martin; A Helenius
Journal:  Cell       Date:  1991-10-04       Impact factor: 41.582

2.  Analysis of the inhibitory effect of canavanine on the replication of influenza RI/5+ virus. I. Inhibition of assembly of RNP.

Authors:  K Maeno; S Yoshii; K Mita; M Hamaguchi; T Yoshida; M Iinuma; Y Nagai; T Matsumoto
Journal:  Virology       Date:  1979-04-15       Impact factor: 3.616

3.  Electron microscopy of the influenza virus submembranal structure.

Authors:  R W Ruigrok; L J Calder; S A Wharton
Journal:  Virology       Date:  1989-11       Impact factor: 3.616

4.  Abortive replication of influenza virus A/WSN/33 in HeLa229 cells: defective viral entry and budding processes.

Authors:  C N Gujuluva; A Kundu; K G Murti; D P Nayak
Journal:  Virology       Date:  1994-11-01       Impact factor: 3.616

5.  Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses.

Authors:  G L Smith; J Z Levin; P Palese; B Moss
Journal:  Virology       Date:  1987-10       Impact factor: 3.616

6.  RNA-binding properties of influenza A virus matrix protein M1.

Authors:  L Wakefield; G G Brownlee
Journal:  Nucleic Acids Res       Date:  1989-11-11       Impact factor: 16.971

7.  Inhibitory effect of protein kinase C inhibitor on the replication of influenza type A virus.

Authors:  M Kurokawa; H Ochiai; K Nakajima; S Niwayama
Journal:  J Gen Virol       Date:  1990-09       Impact factor: 3.891

8.  Nuclear import of microinjected influenza virus ribonucleoproteins.

Authors:  I Kemler; G Whittaker; A Helenius
Journal:  Virology       Date:  1994-08-01       Impact factor: 3.616

9.  Functional expression of influenza A viral nucleoprotein in cells transformed with cloned DNA.

Authors:  K W Ryan; E R Mackow; R M Chanock; C J Lai
Journal:  Virology       Date:  1986-10-15       Impact factor: 3.616

10.  Inhibition of Semliki forest virus penetration by lysosomotropic weak bases.

Authors:  A Helenius; M Marsh; J White
Journal:  J Gen Virol       Date:  1982-01       Impact factor: 3.891

View more
  62 in total

1.  Polyuridylated mRNA synthesized by a recombinant influenza virus is defective in nuclear export.

Authors:  L L Poon; E Fodor; G G Brownlee
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Nuclear export in plants. Use of geminivirus movement proteins for a cell-based export assay.

Authors:  B M Ward; S G Lazarowitz
Journal:  Plant Cell       Date:  1999-07       Impact factor: 11.277

3.  Role of the influenza virus M1 protein in nuclear export of viral ribonucleoproteins.

Authors:  M Bui; E G Wills; A Helenius; G R Whittaker
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Generation of influenza A virus NS2 (NEP) mutants with an altered nuclear export signal sequence.

Authors:  Kiyoko Iwatsuki-Horimoto; Taisuke Horimoto; Yutaka Fujii; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

5.  Using single-particle tracking to study nuclear trafficking of viral genes.

Authors:  Hazen P Babcock; Chen Chen; Xiaowei Zhuang
Journal:  Biophys J       Date:  2004-10       Impact factor: 4.033

6.  Identification and characterization of three novel nuclear export signals in the influenza A virus nucleoprotein.

Authors:  Maorong Yu; Xiaoling Liu; Shuai Cao; Zhendong Zhao; Ke Zhang; Qing Xie; Caiwei Chen; Shengyan Gao; Yuhai Bi; Lei Sun; Xin Ye; George F Gao; Wenjun Liu
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

7.  Interferon-induced human MxA GTPase blocks nuclear import of Thogoto virus nucleocapsids.

Authors:  G Kochs; O Haller
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

8.  Crystal structure of the M1 protein-binding domain of the influenza A virus nuclear export protein (NEP/NS2).

Authors:  Hatice Akarsu; Wilhelm P Burmeister; Carlo Petosa; Isabelle Petit; Christoph W Müller; Rob W H Ruigrok; Florence Baudin
Journal:  EMBO J       Date:  2003-09-15       Impact factor: 11.598

9.  Cytoplasmic domain of influenza B virus BM2 protein plays critical roles in production of infectious virus.

Authors:  Masaki Imai; Kazunori Kawasaki; Takato Odagiri
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

10.  Two African swine fever virus proteins derived from a common precursor exhibit different nucleocytoplasmic transport activities.

Authors:  A Eulálio; I Nunes-Correia; A L Carvalho; C Faro; V Citovsky; S Simões; M C Pedroso de Lima
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.